AbCellera’s First Program with Regeneron in Multi-Target Collaboration Advances in Preclinical Development
02 Novembre 2022 - 2:00PM
Business Wire
AbCellera (Nasdaq: ABCL) announced today that Regeneron has
elected to exercise its right to advance a therapeutic antibody
candidate, discovered in partnership with AbCellera as part of a
multi-target collaboration between the companies, into further
preclinical development. The partnership, which commenced in March
2020 and allows for four discovery programs selected by Regeneron,
leverages AbCellera’s antibody discovery engine and Regeneron’s
VelocImmune® mice to identify novel therapeutic antibodies. This is
the first potential candidate selected by Regeneron to move into
further evaluation, and it targets an undisclosed G-protein coupled
receptor (GPCR).
“By solving technology-intensive challenges that have hindered
antibody discovery against difficult and sought-after drug targets,
we’re able to open up opportunities for leading companies in our
industry,” said Carl Hansen, Ph.D., CEO and President of AbCellera.
“We are pleased our partnership with Regeneron has resulted in this
first early-stage antibody candidate and look forward to continue
empowering drug discovery for Regeneron’s clinical pipeline.”
Under the terms of the agreement, Regeneron has the right to
develop and commercialize therapeutic antibodies resulting from the
collaboration. AbCellera receives research payments and is eligible
to receive downstream clinical and commercial milestone payments
and royalties on net sales of products. AbCellera received a
milestone payment for this antibody candidate and the amount of the
payment was not disclosed.
About AbCellera Biologics Inc.
AbCellera is a technology company that searches, decodes, and
analyzes natural immune systems to find antibodies that its
partners can develop into drugs to prevent and treat disease.
AbCellera partners with drug developers of all sizes, from large
pharmaceutical to small biotechnology companies, empowering them to
move quickly, reduce cost, and tackle the toughest problems in drug
development. For more information, please visit
www.abcellera.com.
AbCellera Forward-looking Statements
This press release contains forward-looking statements,
including statements made pursuant to the safe harbor provisions of
the Private Securities Litigation Reform Act of 1995. The
forward-looking statements are based on management’s current
beliefs and assumptions and on information currently available to
management. All statements contained in this release other than
statements of historical fact are forward-looking statements,
including statements regarding our ability to develop,
commercialize and achieve market acceptance of our current and
planned products and services, our research and development
efforts, and other matters regarding our business strategies, use
of capital, results of operations and financial position, and plans
and objectives for future operations.
In some cases, you can identify forward-looking statements by
the words “may,” “will,” “could,” “would,” “should,” “expect,”
“intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,”
“project,” “potential,” “continue,” “ongoing” or the negative of
these terms or other comparable terminology, although not all
forward-looking statements contain these words. These statements
involve risks, uncertainties and other factors that may cause
actual results, levels of activity, performance, or achievements to
be materially different from the information expressed or implied
by these forward-looking statements. These risks, uncertainties and
other factors are described under "Risk Factors," "Management's
Discussion and Analysis of Financial Condition and Results of
Operations" and elsewhere in the documents we file with the
Securities and Exchange Commission from time to time. We caution
you that forward-looking statements are based on a combination of
facts and factors currently known by us and our projections of the
future, about which we cannot be certain. As a result, the
forward-looking statements may not prove to be accurate. The
forward-looking statements in this press release represent our
views as of the date hereof. We undertake no obligation to update
any forward-looking statements for any reason, except as required
by law.
Source: AbCellera Biologics Inc.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20221031005802/en/
Media: Jessica Yingling, Ph.D.; media@abcellera.com,
+1(236)521-6774 Business Development: Murray McCutcheon, Ph.D.;
bd@abcellera.com, +1(604)559-9005 Investor Relations: Melanie
Solomon; ir@abcellera.com, +1(778)729-9116
Grafico Azioni AbCellera Biologics (NASDAQ:ABCL)
Storico
Da Giu 2024 a Lug 2024
Grafico Azioni AbCellera Biologics (NASDAQ:ABCL)
Storico
Da Lug 2023 a Lug 2024